The Enhanced Effect of Q‐Switched Nd:YAG Laser (1064‐nm) Combined With Glycolic Acid on Keratosis Pilaris: A Split‐Body Randomized Clinical Trial
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/1491351 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Dermatologic Therapy, online erschienen am 03.03.2026. Verfasst von Man Li und 8 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation.
Abstract (Originalsprache)
Background
The Q‐switched Nd:YAG laser (1064‐nm) has been reported to be the best choice for keratosis pilaris (KP) with a high frequency of treatment. Glycolic acid (GA) is known to correct abnormal keratinization and accelerate melanin metabolism. However, the combined effect of Q‐switched Nd:YAG laser (1064‐nm) and GA on KP has not been studied.
Objective
To evaluate the efficacy and safety of combining Q‐switched Nd:YAG laser (1064‐nm) with 30% GA in the treatment of KP.
Method
This prospective, rater‐blinded split‐body comparative study was conducted on patients with bilateral KP on their upper arm. Each participant’s arms were randomly assigned to either the combination group (treated with 30% GA followed by Q‐switched Nd:YAG laser) or the control group (treated with Q‐switched Nd:YAG laser alone). Treatments were administered in four sessions, 3 weeks apart. The primary endpoint was the difference in average physicians’ assessment scores between groups. The secondary endpoints were the patients’ self‐assessment scores, dermoscopic and ultrasonographic improvements, and adverse effects. Clinical, dermoscopic, and ultrasonographic assessments were conducted at baseline and 4 weeks after the final treatment.
Result
A total of 22 patients completed the study. Physicians’ assessment indicated significant improvements in both roughness and redness scores from baseline to final follow‐up in both groups (all p < 0.01). In between‐group comparisons, both physician and patient assessments demonstrated significantly superior improvement in the combination group for roughness, redness, and overall scores compared to the control group (all p < 0.01). Regarding objective measurements, dermoscopic examination showed no significant intergroup differences in the perifollicular erythema and hyperpigmentation (both p > 0.05). However, the combination group led to significantly greater improvement in follicular plugs and, on high‐frequency ultrasound, in the number of epidermal bulges (both p < 0.05). No severe adverse effects were reported in either group.
Conclusion
The combined therapy of Q‐switched Nd:YAG laser (1064‐nm) and 30% GA has the enhanced effect in treating KP, offering significant improvements in skin texture with a favorable safety profile. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2100054489
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Natural Science Foundation
Zitieren
APA
Li, M., Liu, X., Yuan, R., Bai, Y., Duan, Z., Liu, Y., Liang, X., Wu, H., & Zhuo, F. (2026). The Enhanced Effect of Q‐Switched Nd:YAG Laser (1064‐nm) Combined With Glycolic Acid on Keratosis Pilaris: A Split‐Body Randomized Clinical Trial. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1491351
Vancouver
Li M, Liu X, Yuan R, Bai Y, Duan Z, Liu Y, et al. The Enhanced Effect of Q‐Switched Nd:YAG Laser (1064‐nm) Combined With Glycolic Acid on Keratosis Pilaris: A Split‐Body Randomized Clinical Trial. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1491351
BibTeX
@article{Li2026,
author = {Li, Man and Liu, Xiaoduo and Yuan, Ruofei and Bai, Yue and Duan, Zhixuan and Liu, Yi and Liang, Xuelei and Wu, Haixuan and Zhuo, Fenglin},
title = {The Enhanced Effect of Q‐Switched Nd:YAG Laser (1064‐nm) Combined With Glycolic Acid on Keratosis Pilaris: A Split‐Body Randomized Clinical Trial},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/1491351}
}
EUVIMED